Friday, 17 Aug 2018

You are here

Long Term Remission in SLE is Possible?

Researchers from the Toronto Lupus Clinic have described an atypical “monophasic” course in a small number (7.5%) of systemic lupus erythematosus (SLE) patients who achieved and sustained clinical remission, with most off of all medications for an average of 18 years.

Their inception SLE cohort includes patients enrolled within 18 mos of diagnosis.

They defined a monophasic course as a SLEDAI 2000 = 0 (serology excluded) within 5 years since enrollment and maintained for ≥ 10 years of follow-up.

Among their 267 inception SLE patients, 27 (10.1%) achieved prolonged remission (≥ 10 yrs) and 20 (7.5%) sustained remission for the entire followup (average of 18 yrs).

Twelve patients were receiving no maintenance treatment 10 years after achieving remission. Half the patients were still serologically active. Ten years after achieving remission, two-thirds of the patients had discontinued glucocorticosteroids; the remaining were treated with 5 mg/day on average.

Relapse was seen in seven patients (after 10 years), with 4 developing arthritis, 2 lymphadenopathy and 1 with the catastrophic antiphospholipid syndrome.

Remission in lupus is rare but not unheard of.  This single center, expert driven clinic finds a 10% or less chance of remission but that even in these patients relapse, years later, may still be seen; further suggesting the need for prolonged follow up care and guidance in patients with lupus.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ethnicity Matters in Sjogren's Syndrome

Among the ethnically diverse residents of Manhattan, certain groups had markedly different incidence rates of primary Sjogren's syndrome, a retrospective study found.

Women were more often affected, with age-adjusted incidence rates being highest for Asian women, at 10.5 (95% CI 6.6-15.7) per 100,000 person-years, according to Peter M. Izmirly, MD, of New York University School of Medicine in New York City, and colleagues.

Statin Associated with an Increase in Inflammatory Myopathy

JAMA Internal Medicine reports that exposure to statin medications may be linked to histologically confirmed idiopathic inflammatory myositis.

A population-based, case-control study, using the South Australian Myositis Database, examined 221 patients with idiopathic inflammatory myositis (IIM) matched 1:3 with 662 controls. The 221 IIM cases had a mean age of 62.2 years, and 132 (59.7%) were female

Type I Interferon Drives Photosensitivity in Cutaneous Lupus

Kahlenberg and coworkers have reported in ARD that interferon kappa (IFN-κ) is a key regulator of type I interferon (IFN) photosensitive responses in patients with cutaneous lupus erythematosus (CLE).

Latin American Clinical Practice Guidelines for Lupus

The Annals of Rheumatic Disease have published the recently developed Latin American clinical practice guidelines for systemic lupus erythematosus (SLE) addressing the best pharmacologic interventions for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, hematological manifestations and the antiphospholipid syndrome.

Predicting Autoimmune Progression in ANA+ Patients

Positive tests results for antinuclear antibodies (ANAs) are frequently referred to rheumatology despite their poor predictive value, even in individuals who are ‘At Risk’ for autoimmune connective tissue diseases (AI-CTDs). A new study shows that combining ANA positive with interferon-stimulated gene expression increased the liklihood of progression to AI-CTD.